source
- GSK’s $10.6B Nuvalent bet pays off early as FDA approves lung cancer drugJideytro is GSK’s first approved product for lung cancer. With its takeover of Nuvalent Bio last month and a deal with Hansoh Pharmaceutical in 2023, the pharma now has several other lung cancer as…BioSpace · 6d ago↗ source
- Nordic biotech’s next act: From fragmentation to global forceIn this episode of Denatured, you’ll hear from Ester Sklarsky, principal at Sound Bioventures and João Ribas, partner at Novo Holdings Seed Investments. In this episode, we explore the diverging tr…BioSpace · 6d ago↗ source
- Make or break: Commercial hires critical for successWith the stakes for successful launches high, and demand for commercial roles increasing, biopharmas must thoughtfully approach not only hiring but also retention. During a BioSpace webinar, experi…